DNTH: Claseprubart's strong clinical results and pipeline advances are driving rapid growth and expansion
Claseprubart has delivered robust efficacy in MG and CIDP, accelerating trial timelines and market cap growth. The pipeline, including DNTH212 and DNTH312, is advancing rapidly, with MMN and broader neuromuscular indications targeted for future expansion.Based on Dianthus Therapeutics, Inc. [DNTH…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.